Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?

Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?

Advanced hepatocellular carcinoma (HCC) remains a formidable health challenge worldwide, with a 5-year survival rate of 2.4% in patients with distant metastases. The hepatocyte growth factor/cellular-mesenchymal-epithelial transition (HGF/c-Met) signaling pathway represents an encouraging therapeuti...

Full description

Bibliographic Details
Main Authors: Shankun Zhao, Weizhou Wu, Hao Jiang, Lei Ma, Chengyi Pan, Chong Jin, Jinggang Mo, Liezhi Wang, Kunpeng Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Immunology
Subjects:
tivantinib
MET inhibitor
hepatocellular carcinoma
therapeutic effect
adverse event
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.731527/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.731527/full

Similar Items